secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-04-10T23:59:59+00:00
Accession:  0001493152-23-011771
Event type: debt
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem raises ~$490k net via convertible notes at 8%; CEO Pelletier appointed Secretary
--------------------------------------------------------------------------------

- Issued $538,462 principal in senior subordinated convertible notes, 8% interest (12% on default), convertible at $0.01/share.
- Warrants to purchase up to 76.9M shares at $0.01/share, five-year term, with price adjustment provisions.
- Net proceeds ~$490,000; notes mature March 6, 2026; investors paid ~$650 per $1,000 principal.
- CEO Saundra Pelletier appointed as Secretary, replacing Justin J. File who resigned.
- Offering closed on April 5, 2023; notes include change-of-control redemption at 125% premium and various covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223011771/0001493152-23-011771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223011771/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer